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Twin pregnancies are considered a risk factor for preeclampsia, an obstetric complication with 
high maternal and infant morbi-mortality. We hypothesize that alterations in maternal 
hematocrit, plasma lipid peroxidation and nitrates in the first trimester of pregnancy are 
associated with preeclampsia development in twin pregnancies. Blood samples were extracted 
from 102 healthy women with twin pregnancies at tenth week of gestation to assess 
hematological parameters and plasma levels of malondialdehyde and nitrates. Logistic 
regression model showed an association between red blood cells (OR=38.8; p-value=0.009), 
hematocrit (OR=1.6; p-value=0.017), malondialdehyde (OR=1.5; p-value=0.002), and nitrates 
(OR=1.1; p-value=0.045) and preeclampsia development. These parameters are potential 
biomarkers for early preeclampsia detection in twin pregnancies. Future research is needed to 
assess their value in predictive algorithms. 




1. Introduction  
The International Society for the Study of Hypertension in Pregnancy defines preeclampsia as 
de-novo hypertension (systolic blood pressure >140 mm Hg or diastolic blood pressure >90 
mm Hg on two occasions) present after 20 weeks of gestation combined with proteinuria (>300 
mg/day), other maternal organ dysfunction, such as renal insufficiency, liver involvement, 
neurological or hematological complications [1]. Preeclampsia represents between 2-10% of 
the obstetric complications with high rate of morbidity and mortality for mother and fetus [2,3]. 
Twin pregnancies have 2-4 times increased risk to develop preeclampsia compared to singleton 
pregnancies [4]. Preeclampsia is a multifactorial disease, with several possible alterations 
implicated, including abnormal placentation and hypoperfusion, cardiovascular maladaptation, 
or immunological and angiogenic misbalance [5,6]. Some risk factors have been identified, 
including maternal habits (such as smoking) or previous history of preeclampsia. Low dose 
aspirin given to high-risk patients identified in the first trimester is useful as primary prevention 
of preeclampsia [6,7]. However, there are 2 problems. Screening tests in the first trimester need 
implementation, and lack of accurate early detection leads to false negatives, which are 
unnecessarily treated. 
The majority of research on predictive biomarkers has focused on angiogenic factors. However, 
a focus on oxidative stress has been put forward, based on several lines of evidence [6]. 
Misbalance between reactive oxidative species (ROS) and antioxidants is present in 
preeclampsia [7], and elevations of lipid peroxidation products, such as malondialdehyde 
(MDA) are found in plasma at the end of pregnancies complicated with preeclampsia [8]. Other 
possible biomarkers are those related to nitric oxide (NO) metabolism, a potent vasodilator 
with key roles in the hemodynamic adaptation to pregnancy and placental function. 
Preeclampsia has been associated with alterations in NO production or its downstream 
mechanisms of action [9,10]. However, there are some conflicting results. In women with 
preeclampsia, plasma nitrates (which represent NO levels), have been shown to be increased 
in some studies [11,12], while others evidence a decrease [13,14]. Alterations in hematocrit 
can also be considered as potential biomarkers, based on the fact that they are increased in 
women with preeclampsia [15].  
The majority of studies regarding preeclampsia biomarkers have been performed in women 
already diagnosed, and it would be desirable to identify women at risk before the disease is 
developed and to reduce the number of false positives, to avoid unnecessary treatment. The 
aim of our study was to contribute to the knowledge of biomarkers for early diagnosis focused 
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on twin pregnancies, which are a population of high risk.  Based on the evidence in the 
literature, we hypothesize that alterations in hematological parameters, plasma lipid 
peroxidation or nitrates in the first trimester of pregnancy are associated with preeclampsia 
development in twin pregnancies.  
2. Methods  
2.1.Study design  
The prospective study included 102 twin pregnant women, attended at the Obstetrics and 
Gynecology Service from La Paz University Hospital (HULP, Madrid, Spain). Enrolling was 
performed at ninth week of gestation from January 2014 to December 2015. The inclusion 
criteria were healthy women with twin pregnancy. Exclusion criteria were single pregnancy, 
and maternal chronic disease including overweight, previous hypertension, diabetes mellitus, 
kidney, immune and respiratory diseases. The study was performed in accordance with the 
Declaration of Helsinki regarding studies in human and it was approved by HULP Ethical 
Committee (Ref. PI-1490). An informed consent was signed by each participant and 
confidentiality of the data was guaranteed. Blood samples were collected at tenth week of 
gestation. Subjects were followed-up at the HULP until delivery, recording the following data: 
maternal age, gestational age, and preeclampsia (defined as blood pressure above 140/90 
mmHg with proteinuria after 20 weeks of gestation).  
2.2.Maternal biochemical variables at first trimester of pregnancy 
Blood sample was extracted from the participants by using venipuncture in Vacutainer® tubes, 
in fasting state, from 8:00 to 9:00 a.m., following the protocols established by the medical 
staff. The plasma was obtained by centrifugation (2100 rpm, 15 min at 4ºC), within a 
maximum of 2h after extraction. The biochemical and hematological parameters were assayed 
by Laboratory Medicine Service from HULP according to hospital guidelines. The data were 
collected from the obstetrical record.  
Plasma MDA levels were measured by a spectrophotometry in a microplate reader, as 
previously described by Ramiro-Cortijo et at. [16]. Absorbance was measured at 532 nm and 
compared with a standard curve of 1,1,3,3-tetrathoxypropane.  
To assess plasma nitrates, Griess reaction, modified to microplate reader was used, as 




The analysis was performed using R software (version 3.6.0, 2018, R Core Team, Vienna; 
Austria) within R Studio interface. Wilcoxon test was used to compare the difference rank-
sum between groups. Univariate logistic regression was used to associate preeclampsia with 
biochemical variables, and the odd ratios (OR) with 95% confidence intervals were reported. 
Receiver operating characteristics (ROC) curves were used to evaluate the capacity of the 
biochemical variables to predict preeclampsia. The cut-off values, sensitivity and specificity 
were determined. The prediction efficacy was evaluated considering the area under the curve 
(AUC) with 95% confidence interval. Statistical significance was established at p-value<0.05. 
3. Results 
In this cohort, 7.8% (8/102) of the women developed preeclampsia. At the time of delivery, 
maternity age and gestational age were not different between women who developed 
preeclampsia and no-preeclampsia pregnancy. Smoking habits were not different between 
preeclamptic (25.0%) and non-preclamptic women (29,5%; p=0.75). Similarly, primiparity 
rates were not different between and preeclamptic women (37.5%) and non-preclamptic 
women (36,5%; p=0.95). Gestational diabetes (defined as) was present in 12,5% of 
preeclamptic and in 9,4% of non-preeclamptic women (p=0.78). Fetal growth restriction was 
present in 37% of preeclamptic and in 10% of non-preeclamptic women (p<0.05). Low birth 
weight (<1000gr) was present in 75,0% of preeclamptic and in 46,2% of non-preeclamptic 
women (p=0.15). Preterm birth (<37 weeks of gestation), was present in 50% of preeclamptic 
and in 39,3% of non-preeclamptic women (p=0.50).  
At 10 weeks of pregnancy, red blood cells (RBC), hemoglobin, hematocrit, MDA and nitrates 
were significantly higher in women who developed preeclampsia than women without 
preeclampsia (Table 1). Logistic regression showed an association between preeclampsia and 
RBC (OR=38.8 [3.3; ]; p-value=0.009), hematocrit (OR=1.6 [1.1; 2.6]; p-value=0.017), 
MDA (OR=1.5 [1.2; 2.0]; p-value=0.002), and nitrates (OR=1.1 [1.0; 1.2]; p-value=0.045). 
However, hemoglobin did not associate with preeclampsia (OR=1.1 [0.9; 1.2]; p-value=0.33), 
and this parameter was not included in the ROC analysis. RBC, hematocrit, MDA, and nitrates 
had significant differences in the AUC, with sensitivity over 80% and specificity over 65%, as 
shown in table 2. This model support 67% of variability in preeclampsia development. 
4. Discussion  
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This study evidences that hematocrit, lipid peroxidation and NO levels in the first trimester of 
pregnancy are potential biomarkers to be included in predictive algorithms for preeclampsia 
detection in twin pregnancies.   
An early elevation in RBC, hemoglobin and hematocrit were detected in women with twin 
pregnancy who later on developed preeclampsia. Alterations of RBC, hemoglobin, platelets or 
lymphocytes have been found in women with singleton pregnancies already diagnosed with 
preeclampsia [15,18]. Taken together these data and our findings in twin pregnancies, an early 
elevation of maternal hematocrit as potential early biomarker of preeclampsia. It would be 
interesting to analyze in a large population if hematological parameters, regularly detected in 
the first trimester of pregnancy, could be considered in predictive algorithms. Since these 
parameters are routinely assessed in the first trimester of pregnancy, it would be interesting to 
evaluate retrospectively in a large cohort of women, including singleton pregnancies, their 
value as predictive tool, in order to translate this finding to the clinical setting. 
Our data also demonstrate a significantly increase of maternal plasma MDA in women who 
developed preeclampsia. It has been suggested that in preeclampsia, oxidative agents may be 
overproduced due to ischemic-reperfusion injury in the placenta [7]. Lipids are the first targets 
of oxidative damage in there is excessive ROS production [19]. Our data suggest that lipid 
peroxidation may be increased in pregnant women initiating the pathological process, which, 
later on, end up in preeclampsia. Therefore, the possibility that stable products of lipid 
oxidation could be early biomarkers, deserves confirmation in a larger cohort. We assessed 
lipid peroxidation levels by MDA. We are aware of the limitations of this technique, and other 
stable products, such as HNE and F2-isoprostanes, could be assessed. However, none of them 
are devoid of artifacts (Tsikas D. Anal Biochem. 2017 May 1;524:13-30.  doi: 
10.1016/j.ab.2016.10.021).  
Other important molecule for normal vascular function is NO. We found an increase in the 
stable product nitrate, which suggests an overproduction, in agreement with a study in women 
with already established preeclampsia [20, 21]. Our results indicate a systemic upregulation of 
NO pathway, which may be a maternal response to the initiation of a vascular alteration in the 
placenta. Our model support 67% of variability in preeclampsia development. The 
heterogeneous nature of preeclampsia, makes necessary the combination of clinical, 
biophysical and biochemical parameters into multivariate algorithms to predict the disease, 
[22]. Other models studied in single pregnancies had reported 43-63% of variability in the first, 
65-99% in the second, and around 44% in the third trimester. However, fewer models included 
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additional biomarkers, such as pregnancy-associated plasma protein A or placental growth 
factor [23], or emerging risk factors such as lipid peroxidation or NO pathways.  
Our data suggest that hematological parameter, lipid oxidation products and altered NO 
metabolism, may be considered. Regarding the possibility to translate our findings to the 
clinical setting, hematological parameters are routinely assessed in the first trimester of 
pregnancy. Therefore, it would be interesting to assess in a cohort of women with already 
diagnosed preeclampsia, if RBC or hematocrit are of prognostic value. Regarding MDA and 
nitrates need to be assessed by complex methods, such as HPLC-MS, which are not common 
in the clinical setting.  
The present study evidenced that women who developed preeclampsia tended to be older and 
had lower gestational age compared to non-preeclampsia women. The relationship between 
preeclampsia and gestational age [24] or maternal age [25] has been previously found single 
pregnancies. In fact, not only the maternal age but also the paternal age could have an effect 
on pregnancy-induced hypertension diseases [25]. Therefore, together with biochemical 
markers, social and clinical variables should be considered in predictive algorithms. 
5. Conclusions  
Our data demonstrate the relationship between first trimester biochemical and hematological 
alterations, and preeclampsia development in twin pregnancies. Confirmation of our results in 
a larger cohort, could help to conclude on the value of these biomarkers in predictive algorithms 
to identify women at risk. The present work could improve preeclampsia guidelines, 
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Table 1. Maternal characteristics and biochemical parameters according to the development of 
preeclampsia in twin pregnancies.  
Parameters No-Preeclampsia Preeclampsia p-value 
Maternal age (years) 35.0 (32.0; 38.0) 37.5 (33.5; 40.0) 0.31 
Gestational age (weeks) 37.0 (35.0; 38.0) 36.2 (33.8; 37.0) 0.11 
Red blood cells (10
6
/mL) 4.2 (3.9; 4.4) 4.6 (4.5; 4.8) 0.002 
Hemoglobin (g/dL) 13.3 (12.3; 18.9) 14.1 (13.7; 24.5) 0.049 
Hematocrit (%) 38.3 (36.3; 40.0) 41.2 (40.7; 41.8) 0.004 
Leukocytes (10
6
/mL) 8.3 (7.4; 9.8) 7.7 (7.1; 10.0) 0.70 
Platelets (10
3
/mL) 250 (226; 290) 270 (226; 293) 0.79 
Cholesterol (mg/dL) 178 (159; 198) 193 (159; 200) 0.70 
Triglycerides (mg/dL) 94.0 (75.0; 125.0) 124.0 (97.5; 141.3) 0.07 
Total bilirubin (mg/dL) 0.43 (0.36; 0.56) 0.48 (0.38; 0.56) 0.95 
Protein (mg/dL) 6.8 (6.5; 7.0) 6.9 (6.8; 6.9) 0.67 
Uric acid (mg/dL) 3.1 (2.6; 3.4) 3.4 (2.9; 4.2) 0.21 
Glucose (mg/dL) 82.0 (77.0; 88.0) 84.0 (81.5; 104.8) 0.35 
Malondialdehyde (mol/L) 5.5 (3.6; 7.5) 11.0 (9.9; 16.9) 0.001 
Nitrates (M) 2.9 (1.6; 4.7) 7.5 (3.7; 11.7) 0.034 








Table 2. Receiver operating curve for biochemical parameters associated with preeclampsia in 
twin pregnancies.  
 Cut-off Sensitivity Specificity AUC [95% CI] p-value 
Red blood cells (10
6
/mL) 3.98 1.00 0.69 0.87 [0.73; 0.95] 0.002 
Hematocrit (%) 37.0 1.00 0.69 0.85 [0.74; 0.93] 0.005 
Malondialdehyde (mol/L) 3.85 1.00 0.71 0.85 [0.61; 0.95] 0.002 
Nitrates (M) 1.85 0.88 0.70 0.70 [0.49; 0.89] 0.031 
Area Under the Curve (AUC) and 95% of confidence interval (CI). 
 
